A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or ‘bird flu,’ even when given late in the course of illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/outcome/46648/
Close-Up TV News recognizes the NYU Langone Weight Management Program as the country’s premier surgical weight loss facility
The term “morbid obesity” is generally defined as being 100 lbs over the ideal weight or having a Body Mass Index between 35 and 40. Morbid obesity significantly can increase a patient’s risk for diabetes, heart disease and high blood pressure. Unfortunately, for these patients, diet and exercise alone cannot offer a practical solution.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/thinforlife/50245/
Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
LG Chem, la division chimie de LG Group, a signé un partenariat de distribution exclusif pour la France et la Belgique avec Laboderm - filiale de Novomed Group spécialisée en dermatologie et médecine esthétique - pour la distribution de sa gamme YVOIRE, génération innovante de produits de comblement injectables à base d’acide hyaluronique (AH) réticulé d’origine non-animale.
La gamme YVOIRE révolutionne l’offre des produits de comblement. Sa technologie exclusive « HICE » (High Concentration Equalized) se caractérise d’un côté par un haut poids moléculaire pour un effet plus durable et une plus forte élasticité, et de l’autre par une très faible concentration d’agent réticulant BDDE (Butyl Diglycidyl Ether), garantissant plus de sécurité. Au total, sa composition résulte en des produits homogènes, faciles à injecter (fluidité et régularité) et plus résistants à la dégradation enzymatique.
La gamme se décline en trois catégories de produits (« Classic », « Volume », « Contour ») avec ou sans lidocaïne (pour plus de confort), offrant aux praticiens de larges possibilités d’interventions personnalisées selon les patients.
To view the multimedia release go to:
https://www.multivu.com/players/fr/8392651-lg-chem-laboderm-distributeur-yvoire/
Motherhood is a lifelong promise to love, protect and fight for your child. For some mothers, the greatest fight isn’t their own – it’s helping their child battle cancer.
Beginning today and throughout May, Northwestern Mutual, through its Foundation, is honoring heroic moms of childhood cancer patients by sharing their inspiring stories of strength. Additionally, the foundation is making a $50,000 grant in support of these moms to Alex’s Lemonade Stand Foundation (ALSF) to help find a cure.
Northwestern Mutual will share the personal stories of eight mothers and their children from across the country through a Facebook campaign.
To view the multimedia release go to:
http://www.multivu.com/players/English/7730651-northwestern-mutual-mothers-day/
The complete solution to managing vaginal dryness and discomfort inside and out is now available to the millions of women changing physically, emotionally and hormonally every day. The maker of #1 doctor recommended Replens™ vaginal moisturizer introduces hormone-free and fragrance-free Replens™ Moisture Restore External Comfort Gel, for soothing relief from external vaginal dryness, in menopause, post-partum, and after a cancer diagnosis.
“Ladies, don’t despair. Vaginal dryness can be a nuisance at any age. It’s one of the most common symptoms of menopause and unfortunately, can worsen over time. Luckily, there are non-hormonal products like Replens,” says Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University. “I recommend these products to patients as first line therapies to help relieve internal and external vaginal dryness.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8066251-replens-vaginal-moisture-restore-external-comfort-gel/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Mehta Eye Clinic, a leading Eye care specialty clinic in Ghatkopar, Mumbai, has always been on the forefront of technology. With an aspiration to bring the latest and most advanced Eye Care technology for patients, Mehta Eye Clinic has always believed in investing in the best. The Clinic has recently introduced LenSx® -the first of its kind, completely bladeless Laser Assisted Cataract Surgery in the city of Mumbai.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64151-mehta-eye-clinic-laser-cataract-surgery
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
